Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiographic, Clinical and Patient Outcomes in a Multicenter, Open-label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients

Trial Profile

Radiographic, Clinical and Patient Outcomes in a Multicenter, Open-label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RADAR
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Planned End Date changed from 1 Jul 2021 to 1 Jul 2015, according to ClinicalTrials.gov record.
    • 27 Jan 2015 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2015, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top